A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer.
File(s)
Published version
Author(s)
Fleming, Katy
McGuinness, James
Kipgen, David
Glen, Hilary
Spiliopoulou, P
Type
Journal Article
Abstract
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now.
Date Issued
2018-10-03
Date Acceptance
2018-09-13
Citation
Case Reports in Oncological Medicine, 2018, 2018
ISSN
2090-6706
Publisher
Hindawi Publishing Corporation
Journal / Book Title
Case Reports in Oncological Medicine
Volume
2018
Copyright Statement
© 2018 Kathryn Fleming et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
ENDOTHELIAL GROWTH-FACTOR
ADVANCED SOLID TUMORS
TYROSINE KINASE INHIBITOR
RANDOMIZED PHASE-III
CELL LUNG-CANCER
THROMBOTIC MICROANGIOPATHY
COLORECTAL-CANCER
ANGIOGENESIS INHIBITION
INTERSTITIAL NEPHRITIS
VEGF INHIBITION
Publication Status
Published
Article Number
6927639